73 related articles for article (PubMed ID: 17214360)
1. Quantification in the serum of the catalytic fraction of reverse telomerase: a useful prognostic factor in advanced non-small cell lung cancer.
Camps C; Sirera R; Bremnes RM; Ródenas V; Blasco A; Safont MJ; Garde J; Juarez A; Caballero C; Sanchez JJ; Taron M; Rosell R
Anticancer Res; 2006; 26(6C):4905-9. PubMed ID: 17214360
[TBL] [Abstract][Full Text] [Related]
2. Circulating DNA is a useful prognostic factor in patients with advanced non-small cell lung cancer.
Sirera R; Bremnes RM; Cabrera A; Jantus-Lewintre E; Sanmartín E; Blasco A; Del Pozo N; Rosell R; Guijarro R; Galbis J; Sánchez JJ; Camps C
J Thorac Oncol; 2011 Feb; 6(2):286-90. PubMed ID: 21252717
[TBL] [Abstract][Full Text] [Related]
3. hTERT expression is a prognostic factor of survival in patients with stage I non-small cell lung cancer.
Wang L; Soria JC; Kemp BL; Liu DD; Mao L; Khuri FR
Clin Cancer Res; 2002 Sep; 8(9):2883-9. PubMed ID: 12231532
[TBL] [Abstract][Full Text] [Related]
4. Increased human telomerase reverse transcriptase (hTERT) mRNA expression but not telomerase activity is related to survival in curatively resected non-small cell lung cancer.
Metzger R; Vallbohmer D; Müller-Tidow C; Higashi H; Bollschweiler E; Warnecke-Eberz U; Brabender J; Baldus SE; Xi H; Berdel WE; Serve H; Hoelscher AH; Schneider PM
Anticancer Res; 2009 Apr; 29(4):1157-62. PubMed ID: 19414359
[TBL] [Abstract][Full Text] [Related]
5. The diagnostic and prognostic relevance of human telomerase reverse transcriptase mRNA expression detected in situ in patients with nonsmall cell lung carcinoma.
Fujita Y; Fujikane T; Fujiuchi S; Nishigaki Y; Yamazaki Y; Nagase A; Shimizu T; Ohsaki Y; Kikuchi K
Cancer; 2003 Sep; 98(5):1008-13. PubMed ID: 12942569
[TBL] [Abstract][Full Text] [Related]
6. Circulating plasma DNA as diagnostic biomarker in non-small cell lung cancer.
Paci M; Maramotti S; Bellesia E; Formisano D; Albertazzi L; Ricchetti T; Ferrari G; Annessi V; Lasagni D; Carbonelli C; De Franco S; Brini M; Sgarbi G; Lodi R
Lung Cancer; 2009 Apr; 64(1):92-7. PubMed ID: 18804892
[TBL] [Abstract][Full Text] [Related]
7. Telomerase activity and expression of the telomerase catalytic subunit gene in non-small cell lung cancer: correlation with decreased apoptosis and clinical prognosis.
Wang J; Liu X; Jiang W; Liang L
Chin Med J (Engl); 2000 Nov; 113(11):985-90. PubMed ID: 11776132
[TBL] [Abstract][Full Text] [Related]
8. Do the time to chemotherapy response and the dose intensity have an impact on patient outcome in advanced non-small cell lung cancer?
Radosavljevic D; Golubicic I; Gavrilovic D; Kezic I; Jelic S
J BUON; 2009; 14(2):203-9. PubMed ID: 19650167
[TBL] [Abstract][Full Text] [Related]
9. The favorable prognostic significance of atelectasis in patients with advanced non-small cell lung cancer: results of a prospective observational study.
Dediu M; Crisan E; Radut M; Tarlea A; Median D; Alexandru A; Vremes G; Gal C
Lung Cancer; 2009 Feb; 63(2):271-6. PubMed ID: 18565617
[TBL] [Abstract][Full Text] [Related]
10. [Relationship among telomerase activity, telomerase RNA and telomerase catalytic subunit gene expression and their significance in non small-cell lung cancer].
Wang J; Liu X; Jiang W
Zhonghua Zhong Liu Za Zhi; 2001 Jul; 23(4):289-92. PubMed ID: 11783109
[TBL] [Abstract][Full Text] [Related]
11. Telomerase activity in transthoracic fine-needle biopsy aspirates from non-small cell lung cancer as prognostic factor of patients' survival.
Targowski T; Jahnz-Rózyk K; Szkoda T; Płusa T; From S
Lung Cancer; 2008 Jul; 61(1):97-103. PubMed ID: 18063440
[TBL] [Abstract][Full Text] [Related]
12. Elevation of telomerase activity positively correlates to poor prognosis of patients with non-small cell lung cancer.
Chen KY; Lee LN; Yu CJ; Lee YC; Kuo SH; Yang PC
Cancer Lett; 2006 Aug; 240(1):148-56. PubMed ID: 16249053
[TBL] [Abstract][Full Text] [Related]
13. Effect of vascular endothelial growth factor polymorphisms on survival in advanced-stage non-small-cell lung cancer.
Masago K; Fujita S; Kim YH; Hatachi Y; Fukuhara A; Nagai H; Irisa K; Ichikawa M; Mio T; Mishima M
Cancer Sci; 2009 Oct; 100(10):1917-22. PubMed ID: 19594543
[TBL] [Abstract][Full Text] [Related]
14. Quantification of free circulating DNA as a diagnostic marker in lung cancer.
Sozzi G; Conte D; Leon M; Ciricione R; Roz L; Ratcliffe C; Roz E; Cirenei N; Bellomi M; Pelosi G; Pierotti MA; Pastorino U
J Clin Oncol; 2003 Nov; 21(21):3902-8. PubMed ID: 14507943
[TBL] [Abstract][Full Text] [Related]
15. Pretreatment neutrophil count as an independent prognostic factor in advanced non-small-cell lung cancer: an analysis of Japan Multinational Trial Organisation LC00-03.
Teramukai S; Kitano T; Kishida Y; Kawahara M; Kubota K; Komuta K; Minato K; Mio T; Fujita Y; Yonei T; Nakano K; Tsuboi M; Shibata K; Furuse K; Fukushima M
Eur J Cancer; 2009 Jul; 45(11):1950-8. PubMed ID: 19231158
[TBL] [Abstract][Full Text] [Related]
16. Tumor expression of S100A6 correlates with survival of patients with stage I non-small-cell lung cancer.
De Petris L; Orre LM; Kanter L; Pernemalm M; Koyi H; Lewensohn R; Lehtiö J
Lung Cancer; 2009 Mar; 63(3):410-7. PubMed ID: 18620780
[TBL] [Abstract][Full Text] [Related]
17. Is there a prognostic role of K-ras point mutations in the serum of patients with advanced non-small cell lung cancer?
Camps C; Sirera R; Bremnes R; Blasco A; Sancho E; Bayo P; Safont MJ; Sánchez JJ; Tarón M; Rosell R
Lung Cancer; 2005 Dec; 50(3):339-46. PubMed ID: 16139926
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of circulating chromogranin A and soluble tumor necrosis factor receptors in advanced nonsmall cell lung cancer.
Gregorc V; Spreafico A; Floriani I; Colombo B; Ludovini V; Pistola L; Bellezza G; Viganò MG; Villa E; Corti A
Cancer; 2007 Aug; 110(4):845-53. PubMed ID: 17599769
[TBL] [Abstract][Full Text] [Related]
19. Cisplatin plus weekly vinorelbine versus cisplatin plus vinorelbine on days 1 and 8 in advanced non-small cell lung cancer: a prospective randomized phase III trial of the G.O.I.M. (Gruppo Oncologico Italia Meridionale).
Gebbia V; Galetta D; Lorusso V; Caruso M; Verderame F; Pezzella G; Borsellino N; Durini E; Valenza R; Agostara B; Colucci G;
Lung Cancer; 2008 Sep; 61(3):369-77. PubMed ID: 18308419
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of telomeric repeat length alterations in pathological stage I-IIIA non-small cell lung cancer.
Hirashima T; Komiya T; Nitta T; Takada Y; Kobayashi M; Masuda N; Matui K; Takada M; Kikui M; Yasumitu T; Ohno A; Nakagawa K; Fukuoka M; Kawase I
Anticancer Res; 2000; 20(3B):2181-7. PubMed ID: 10928174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
